Roche Tecentriq wins European nod for breast cancer
The European Commission approved Tecentriq with Abraxane for people with metastatic triple-negative breast cancer that tests positive for a protein believed to help tumours to evade attack by the body's immune system, Roche said on Thursday.
ZURICH: Roche's Tecentriq has won European approval for use against tough-to-treat breast cancer, helping the Swiss drugmaker to widen the use of immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines.
The European Commission approved Tecentriq with Abraxane for people with metastatic triple-negative breast cancer that tests positive for a protein believed to help tumours to evade attack by the body's immune system, Roche said on Thursday.
Tecentriq trailed rival immunotherapies Keytruda and Opdivo - produced by Merck and Bristol-Myers Squibb respectively - to market but has been racking up approvals.
These include approvals for niche indications such as metastatic triple-negative breast cancer. Some 15-20% of breast cancer is triple-negative, meaning tumours lack three characteristics for which there are more treatment options.
"The European approval of this Tecentriq combination represents a significant step forward in the treatment of this aggressive breast cancer, where the unmet medical need is great," Roche Chief Medical Officer Sandra Horning said in a statement.
Read Also: Roche names Eli Lilly executive Levi Garraway as chief medical officer
Tecentriq, having steadily added approvals in new cancer indications and new geographies, is on track to surpass $1.5 billion in annual sales in 2019, its third full year on the market.
Opdivo and Keytruda, which had a two-year head start on Tecentriq, achieved sales of $6.7 billion and $7.2 billion respectively in 2018.
Read Also: Roche personalized cancer treatment Rozlytrek priced at Rs 12 lakh per month
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd